A Phase 2 interventional study of Arm A:Dose_dense Capecitabine in Colorectal cancer and Arm B : standard dose Capecitabine in Colorectal Cancer, sponsored by Sohag University. Active, not recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-14.
Sponsored by Sohag University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Colorectal Neoplasms with a site in Egypt — 15 open to participants now, 17 under way, 5 of them phase 3. Colorectal Neoplasms · Egypt.
Among the 55 studies in Colorectal Neoplasms with a site in Egypt, this one is the 8th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2025, is one of 5 in phase 2, reaches primary completion later than 14 of the 16 other live ones, and was the 46th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →15 of the 55 studies in Colorectal Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 18+
Ahmed Adel Ahmed Elsayed Ali Radwan · Sites in Egypt
Ages 40–59
Minia University · Sites in Egypt
Ages 18–80
Sohag University · Sites in Egypt
Ages 18–80
Sohag University · Sites in Egypt
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 13 · Phase 4 1
First in 1999; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 60 across the 31 interventional studies, 96 across the 23 observational. Of the 29 that completed or were terminated, 2 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 55 have an industry lead sponsor. The 10 most frequent:
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
Sohag University has 9 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Colorectal Neoplasms with a site in Egypt that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07736495Phase 3Ain Shams UniversityProtective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis | 2026-12-27 |
| NCT07922642Alexandria UniversityNurse-Led Prehabilitation Before Major Abdominal Cancer Surgery | 2027-02-05 |
| NCT07144683Minia UniversityAnastomotic Leakage After Colorectal Surgery. | 2027-03-25 |
| NCT07874035Ahmed Adel Ahmed Elsayed Ali RadwanLow Load Blood Flow Restriction Resistance Training in Colorectal Cancer Related Sarcopenia | 2027-08-15 |
| NCT07215936Sohag UniversityDose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 55 studies in Colorectal Neoplasms with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dose_dense Capecitabine Schedule in colorectal cancers
Dose_dense Capecitabine schedule[7 days on_7days off] in colorectal cancer in comparison with standerd regimen
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Arm A:Dose_dense Capecitabine in Colorectal cancer
Drug: Arm B : standard dose Capecitabine
Appling dose \_dense Capecitabine 1750mg/m2 for one week then one week off Cycle repeated every 2 weeks
Pateints will receive capecitabine 1000 mg/m2 for 2 weeks then one week off
1_Quality of life assessed through EORTC_QLQ_CR29 questionaire
Time frame: 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.
Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 24 months is below that.
Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.